Scimega launches Reverse Feasibility Resource Center to attract oncology trials to Canada
Scimega Research, a Canadian-based oncology CRO with a mission to attract cutting-edge oncology trials to Canada, has launched its new Reverse Feasibility Resource Center, a unique initiative that complements its Reverse Feasibility Program, which matches the patient recruitment needs of U.S. oncology sponsors with the scientific interests of Canadian investigators and the treatment needs of their patients.
This microsite will enhance sponsor access to the program by providing regular updates that highlight Canada’s experience in both early and late phase oncology trials. Currently, it features important information such as the number of oncology sites, key investigators and catchment area size for each of the 10 Canadian provinces.
Sponsors can sign up to receive free quarterly updates on the types of trials Scimega’s Reverse Feasibility Champions are looking to participate in. The Oncology Trial Needs Report for Canada will highlight the number of sites actively looking for trials, based on lines of treatment, tumor types and targets.
“The Reverse Feasibility Program was launched in 2009 to attract state-of-the-art clinical research to Canada,” said Denise Deakin, president and co-founder of Scimega Research. “It was founded on the premise that long-standing relationships between Scimega and top performing oncology sites could be leveraged by sponsors to maximize the performance and quality of their trials, while enhancing the overall clinical trial experience for both investigators and patients.”
"Using this approach, we've seen as much as a 50% reduction in study start-up times, while meeting targeted patient recruitment objectives. It's really proven to be a win-win situation as sponsors are thrilled with the performance metrics, while clinicians and their patients are happy to participate in well designed, cutting-edge trials. We're hoping the new Resource Center will help facilitate many more of these positive experiences."